NCT06876142View on ClinicalTrials.gov

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 28, 2025

Primary Completion Date

January 1, 2033

Study Completion Date

January 1, 2033

Conditions
Multiple MyelomaRelapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions
DRUG

Mirdametinib

Capsules taken by mouth twice a day (2-12mg) for days 1-21 days of each 28 day cycle

DRUG

Sirolimus

Tablets taken by mouth once a day for days 1-28 days of each 28 day cycle. Loading dose of 12 mg on Day 1 Cycle 1 with 4 mg being taken for the remaining doses.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH